{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-007867","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.935907+00:00","generated_at":"2026-06-17T17:05:48.713913+00:00","sec_items":["2.03","3.02"],"event_type":"litigation","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SAB Biotherapeutics settles Ladenburg lawsuit; issues warrant and agrees to pay $3.1M","bullets":["Issued warrant for 300,000 shares at $0.5424 per share and paid $500K cash upfront.","Must pay $1.5M by June 30, 2023, and $1.1M by Dec 31, 2023, in cash or stock at Company's option.","Ladenburg Action will be dismissed with prejudice after obligations completed.","Warrant issued under Section 4(a)(2) and Rule 506 of Regulation D as unregistered sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-007867","json":"https://secwatch.observer/filing/0001437749-23-007867.json","markdown":"https://secwatch.observer/filing/0001437749-23-007867.md","text":"https://secwatch.observer/filing/0001437749-23-007867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923007867/0001437749-23-007867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923007867/sabs20230324_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T17:05:48.713913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e7f8b2394a9d240fe775863b09f3da5cd6c4313","claim":"SAB Biotherapeutics, Inc. incurred debt of pay $1.5 million to Ladenburg in cash or shares of common stock, at the Company’s option; and (ii) no later than Decembe with Ladenburg Thalmann & Co. Inc. maturing December 31, 2023.","evidence_excerpt":"On March 21, 2023, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a settlement agreement with Ladenburg Thalmann & Co. Inc. (the “2023 Ladenburg Agreement”, and the action brought by Ladenburg, the “Ladenburg Action”), effective March 23, 2023.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923007867/0001437749-23-007867-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Principal","value":"pay $1.5 million to Ladenburg in cash or shares of common stock, at the Company’s option; and (ii) no later than Decembe"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Maturity","value":"December 31, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}